Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Alpha interferon and Alzheimer's disease].

J A Cabrera-Gómez1, P López-Saura

  • 1Servicio de Neurología, Hospital Gustavo Aldereguía Lima, Cienfuegos, Cuba. cabrera@jagua.cfg.sld.cu

Revista De Neurologia
|April 1, 2000
PubMed
Summary

Alpha interferon (IFN-alpha) treatment showed potential in stabilizing neurological signs in an Alzheimer's disease (AD) patient. While a clinical trial revealed no significant neurophysiological changes, quality of life improved and mortality decreased in AD patients treated with IFN-alpha.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recombinant streptokinase suppositories in the treatment of acute haemorrhoidal disease. Multicentre randomized double-blind placebo-controlled trial (THERESA-2).

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2013
Same author

Fluctuations of MS births and UV-light exposure.

Acta neurologica Scandinavica·2012
Same author

Conventional brain MRI in neuromyelitis optica.

European journal of neurology·2011
Same author

Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications.

Neurology·2011
Same author

Absence of cortical demyelination in neuromyelitis optica.

Neurology·2010
Same author

Multiple sclerosis and solar exposure before the age of 15 years: case-control study in Cuba, Martinique and Sicily.

Multiple sclerosis (Houndmills, Basingstoke, England)·2010

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Alzheimer's disease (AD) is the most common cause of dementia with unknown etiology and non-specific treatments.
  • Interferons (IFN) possess antiviral, antiproliferative, and immunomodulatory effects, potentially mediated via opiate and dopaminergic systems in the central nervous system.
  • Evidence suggests a link between AD, prion diseases, and viral infections, with a compromised IFN system observed in AD patients.

Purpose of the Study:

  • To review patients with Alzheimer's disease (AD) treated with alpha interferon (IFN-alpha).
  • To evaluate the efficacy of IFN-alpha in managing neurological and quality of life aspects of AD.

Main Methods:

  • Case report of a 69-year-old male with definite AD treated intrathecally with alpha leucocytic IFN, initially suspected of Creutzfeldt-Jakob disease.

Related Experiment Videos

  • Analysis of a controlled, randomized clinical trial involving 16 patients with probable AD treated intramuscularly with recombinant IFN-alpha 2b for one year.

    • Main Results:

    • The initial case showed stabilization of neurological signs after intrathecal IFN-alpha treatment.
    • The clinical trial found no changes in clinical or neurophysiological assessments after one year of intramuscular IFN-alpha 2b.
    • A significant improvement in a quality of life variable and a reduction in mortality were observed in the IFN-alpha treated group.

    Conclusions:

    • IFN-alpha may offer benefits in quality of life and mortality reduction for Alzheimer's disease patients.
    • Future studies should investigate the role of pro-inflammatory cytokines in AD neurodegeneration and how IFN-alpha might counteract their effects.
    • IFN-alpha's ability to block actions of pro-inflammatory cytokines warrants further exploration in the context of AD pathogenesis.